Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
Dan-Bee Park1*, Kyungho Jang1, 2*, Jae-Won Lee3, Cheol-Won Park3, Back-Hwan Lee3, Min-Gul Kim1,4, Ji-Young Jeon1
1 Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonju, 2 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, 3 Research & Development Division, Alvogen Korea CO., Ltd., and 4 Department of Pharmacology, School of Medicine, Chonbuk National University, Jeonju, Republic of Korea
DOI 10.5414/CP202740
Abstract
Context: A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to enhance patient compliance. Objective: This study was performed to compare the single-dose pharmacokinetic properties and tolerability of DP-R208 (candesartan and rosuvastatin FDC) to those of each component administered alone in healthy Korean male volunteers. Materials and Methods: A total of 40 healthy Korean volunteers were enrolled in this randomized, open-label, single-dose, two-treatment, two-way crossover study. During each treatment period, subjects received the test formulation (FDC tablet containing candesartan and rosuvastatin) or reference formulation (co-administration of candesartan and rosuvastatin). Plasma samples were collected pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours post-dose. Safety and tolerability were assessed by the evaluation of adverse events (AEs), physical examinations, laboratory assessments, 12-lead electrocardiograms (ECGs), and vital sign measurements. Results: The 90% confidence intervals (CIs) of the geometric least-square mean ratios of Cmax, AUClast, and AUCinf were 0.86 – 1.00, 0.92 – 1.04, and 0.92 – 1.03 for candesartan, and 0.88 – 1.06, 0.91 – 1.08, and 0.91 – 1.03 for rosuvastatin, respectively. All of the AEs were mild, and there was no significant difference in the incidence of AEs between the formulations. Furthermore, the pharmacokinetic properties of the test and reference formulations met the regulatory criteria for bioequivalence. Discussion and conclusion: Both formulations were safe and well tolerated, and no significant difference was observed in the safety assessments of the treatments.
Author Details
Authors
Departments
- 1 Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Jeonju,
- 2 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul,
- 3 Research & Development Division, Alvogen Korea CO., Ltd., and
- 4 Department of Pharmacology, School of Medicine, Chonbuk National University, Jeonju, Republic of Korea
Address
Ji-Young Jeon, PhD
Center for Clinical Pharmacology and Biomedical Research Institute
Chonbuk National University Hospital
20, Genji-ro, Deokjin-gu, Jeonju-si,
Jeollabuk-do 54907, Korea
Email:
[email protected]
Citation
Dan-Bee Park, Kyungho Jang, Jae-Won Lee, Cheol-Won Park, Back-Hwan Lee, Min-Gul Kim, and Ji-Young Jeon. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
. 2017; 55: 286-294. doi: 10.5414/CP202740.